Abstract
BackgroundIn Japan, rituximab (RTX) has become one of the dominant alternatives for ANCA associated vasculitis (AAV) even for elderly patients.ObjectivesThe efficacy and safety of RTX for AAV patients was determined...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
